Medpace Holdings Tidigare resultatutveckling
Tidigare kriterier kontrolleras 4/6
Medpace Holdings har ökat intäkterna med en genomsnittlig årlig takt på 21.6%, medan Life Sciences -branschen såg intäkterna minskar på 3.8% årligen. Intäkterna har varit växande med en genomsnittlig takt på 19% per år. Medpace Holdings s avkastning på eget kapital är 76.9% och den har en nettomarginal på 17.2%.
Viktig information
21.61%
Tillväxttakt i vinsten
25.60%
Tillväxttakt för EPS
| Life Sciences Tillväxt i branschen | 21.51% |
| Intäkternas tillväxttakt | 19.01% |
| Avkastning på eget kapital | 76.95% |
| Nettomarginal | 17.19% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Uppdatering av berättelse • May 14
MEDP: Slower Long Term Revenue Assumptions Will Challenge Rich P E Multiple
Medpace Holdings' fair value estimate has been trimmed by about $7 to $349.93 as analysts moderate long term revenue growth assumptions, while still recognizing higher profit margins and a slightly higher forward P/E in their updated price targets. Analyst Commentary Recent Street research on Medpace highlights a mix of cautious and constructive views, with several firms revising price targets and ratings as they reassess growth assumptions, margins, and sector trends in clinical research outsourcing.
Uppdatering av berättelse • Apr 29
MEDP: Biotech Trial Efficiency And AI Savings Will Support Future Margin Resilience
Medpace Holdings' analyst price target has been reset from about $582 to roughly $495 as analysts factor in updated assumptions for revenue growth, margins and future P/E multiples, while still pointing to company specific strengths highlighted in recent research coverage and upgrades. Analyst Commentary Street research around Medpace has recently centered on recalibrating price targets while still emphasizing company specific strengths.Analysartikel • Apr 26
Medpace Holdings, Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Shareholders in Medpace Holdings, Inc. ( NASDAQ:MEDP ) had a terrible week, as shares crashed 21% to US$411 in the week...Seeking Alpha • Apr 24
Medpace Holdings: Downgrade To 'Buy' As Revenue Growth Remains, But With Caution Ahead
Summary Medpace Holdings is downgraded from 'Strong Buy' to 'Buy' due to rising backlog cancellations and elevated direct costs, despite robust revenue growth. MEDP delivered Q1 2026 revenue of $706.6M (+26.5% YoY) and beat both top- and bottom-line expectations, with strong Net New Business Awards growth. The Net Book-to-Bill ratio fell to 0.88x in Q1 2026, driven by the highest backlog cancellations in over a year, warranting caution. Full-year 2026 revenue guidance is raised to $2.755B–$2.855B, but persistent cancellation and cost risks could prompt further rating downgrades. Read the full article on Seeking AlphaUppdatering av berättelse • Apr 15
MEDP: Slower Revenue Assumptions Will Test Rich Multiple And 2026 Execution
Medpace Holdings' analyst-derived fair value has inched up by about $5 to roughly $357, as analysts weigh higher assumed profit margins and a richer future P/E against slower projected revenue growth and a slightly higher discount rate, while incorporating a wave of recent rating upgrades and higher price targets clustered around $419 to $522. Analyst Commentary Recent research on Medpace reflects a mix of upgrades and cautious fine tuning, with several firms lifting ratings while keeping a close eye on valuation, end market trends, and execution risk.
Uppdatering av berättelse • Apr 01
MEDP: Efficient Biotech Contracts And Buybacks Will Support Elevated Market Expectations
Analysts have inched up their blended price target on Medpace Holdings to about $500 per share from roughly $490, citing the company’s efficiency in contract research, ongoing biotech-focused wins, and a series of recent rating upgrades as key reasons for this recalibration. Analyst Commentary Recent research remains broadly constructive on Medpace, with several firms adjusting ratings and price targets as they reassess valuation, execution, and exposure to biotech customers.Uppdatering av berättelse • Mar 18
MEDP: Biotech Trial Efficiency And AI Savings Will Support Future Margin Strength
Analysts have nudged their overall price expectations for Medpace modestly higher, reflected in a slightly lower discount rate of 7.78% and small upward tweaks to revenue growth and profit margin assumptions. These changes are supported by a series of recent rating upgrades and fresh price targets in the $419 to $660 range.Uppdatering av berättelse • Mar 03
MEDP: Efficiency And Biotech Exposure Will Support Margin Strength Going Forward
Analysts have lifted their implied fair value estimate for Medpace Holdings to $582 from $510, citing the company's efficiency as a contract research organization, stronger profit margin assumptions at 17.94%, and a higher future P/E of about 29.35x as key supports for the updated price targets across recent research. Analyst Commentary Recent research coverage has highlighted a generally constructive tone around Medpace, with several bullish analysts pointing to efficiency, exposure to biopharma clients, and margin profile as key parts of the equity story.Uppdatering av berättelse • Feb 17
MEDP: Higher Margins And Buybacks Will Support Rich Market Expectations
Analysts have trimmed their average price target on Medpace Holdings by about $55 to $490.50 as revised models reflect updated revenue growth assumptions, a slightly different discount rate, higher expected profit margins, and a higher future P/E multiple, informed by a mix of recent upgrades and target changes across the Street. Analyst Commentary Recent research has produced a mix of upgrades and target cuts, with Street views clustering around how sustainable Medpace Holdings' growth, margins, and valuation may be after the latest earnings move.Analysartikel • Feb 13
Medpace Holdings, Inc. (NASDAQ:MEDP) Just Reported, And Analysts Assigned A US$491 Price Target
Shareholders in Medpace Holdings, Inc. ( NASDAQ:MEDP ) had a terrible week, as shares crashed 23% to US$416 in the week...Uppdatering av berättelse • Feb 03
MEDP: Decelerating Healthcare Utilization Will Test Rich Multiple And 2026 Execution
Analysts have nudged their price target for Medpace Holdings slightly higher, to $660 from $655, citing updated Q4 healthcare utilization survey findings and modest tweaks to growth, margin and future P/E assumptions in their models. Analyst Commentary Recent research around Medpace focuses on how healthcare utilization trends could influence growth expectations, margins and the valuation investors are willing to pay.Uppdatering av berättelse • Jan 20
MEDP: Biotech Recovery And Backlog Strength Will Challenge Rich Market Expectations
Narrative Update: Medpace Holdings Analyst Price Target Shift The updated analyst framework edges fair value for Medpace Holdings slightly higher to about $545.75 from roughly $541.92. This reflects modest tweaks to discount rate, growth, margin and P/E assumptions as analysts respond to a series of recent price target increases across the Street.Uppdatering av berättelse • Jan 06
MEDP: Rich Multiple Will Depend On Unproven 2026 Execution
Analysts raised their fair value estimate for Medpace Holdings from about $305 to roughly $356 per share, citing higher assumed revenue growth, slightly improved profit margins, and a modestly higher future P/E multiple in line with recent Street price target increases. Analyst Commentary Recent Street research on Medpace highlights a mix of optimism on the long term setup and caution around how much upside is already reflected in the current share price.Uppdatering av berättelse • Dec 21
MEDP: Biotech Funding Recovery And Backlog Trends Will Shape Future Prospects
Analysts have nudged their blended fair value estimate for Medpace Holdings slightly higher, to approximately $542 from $539, citing increased confidence in the durability of biotech recovery, a healthier pre-backlog pipeline, and signs that contract research trends have stabilized. Analyst Commentary Street research updates over the last several weeks reflect a generally constructive stance on Medpace, with multiple firms raising price targets while maintaining a range of ratings from Sell to Outperform.Uppdatering av berättelse • Dec 07
MEDP: Biotech Funding Recovery And Book-To-Bill Trends Will Shape Future Outlook
Analysts have nudged their price target on Medpace Holdings modestly higher by about $2 per share to reflect increased confidence in a sustained recovery in biotech funding, healthier book to bill trends, and signs that contract research organization demand has likely stabilized. Analyst Commentary Recent Street research reflects a more constructive stance on Medpace, with several bullish analysts lifting price targets to account for stronger sector fundamentals and improved visibility into the company’s growth trajectory.Uppdatering av berättelse • Nov 22
MEDP: Improving Biotech Pipeline And Book-To-Bill Trends Will Support Recovery Momentum
The analyst price target for Medpace Holdings has increased from $519 to $538. Analysts cite improving Biotech market confidence and stronger forward earnings projections as factors supporting this upward revision.Uppdatering av berättelse • Nov 07
MEDP: Below-Normal Bookings In 2025 Will Pressure Revenue Expansion
Analysts have raised their price target for Medpace Holdings from $456 to approximately $519, citing higher growth estimates and renewed confidence in the CRO sector's recovery. Analyst Commentary Bullish Takeaways Bullish analysts have raised price targets for Medpace, citing increased confidence in the recovery trajectory of the biotech sector and the broader contract research organization market.Uppdatering av berättelse • Oct 24
Future Sector Demand Shifts Will Influence Risk And Reward Dynamics
Analysts have raised their fair value estimate for Medpace Holdings to $456 from $428 per share. This change reflects updated optimism based on recent price target adjustments and expectations for stabilization in contract research organization demand trends.Uppdatering av berättelse • Oct 09
Tech-enabled Clinical Trials Will Balance Potential Risk And Reward
Analysts have raised Medpace Holdings’ fair value estimate modestly, from $423.64 to $428.00. Industry views reflect improved biotech funding and solid bookings, although some ongoing uncertainty in demand signals remains.Uppdatering av berättelse • Sep 04
Tech-enabled Clinical Trials Will Balance Potential Risk And Reward
As key metrics including the discount rate (7.16%) and net profit margin (16.85%) remained stable, the consensus analyst price target for Medpace Holdings was unchanged at $422.27. What's in the News Medpace completed a repurchase of 1,754,264 shares (5.89% of shares outstanding) for $518.54 million in Q2 2025, bringing the total buyback under its current program to 14.76% of shares outstanding and $1.27 billion since October 2022 (Key Developments).Analysartikel • Aug 11
Earnings Not Telling The Story For Medpace Holdings, Inc. (NASDAQ:MEDP) After Shares Rise 34%
Medpace Holdings, Inc. ( NASDAQ:MEDP ) shareholders have had their patience rewarded with a 34% share price jump in the...Analysartikel • Jul 24
Medpace Holdings, Inc. Beat Revenue Forecasts By 12%: Here's What Analysts Are Forecasting Next
As you might know, Medpace Holdings, Inc. ( NASDAQ:MEDP ) just kicked off its latest second-quarter results with some...Analysartikel • Jul 01
Should You Think About Buying Medpace Holdings, Inc. (NASDAQ:MEDP) Now?
Medpace Holdings, Inc. ( NASDAQ:MEDP ), might not be a large cap stock, but it saw a double-digit share price rise of...Analysartikel • Jun 12
Is Medpace Holdings, Inc. (NASDAQ:MEDP) Trading At A 48% Discount?
Key Insights The projected fair value for Medpace Holdings is US$587 based on 2 Stage Free Cash Flow to Equity Medpace...Seeking Alpha • Feb 06
Medpace: Impressive Revenue Growth, High ROE Values, And High Growth Potential
Summary Medpace has had an excellent financial performance. Its revenues increased by 495.26% between 2016Q2 and 2024Q3. Meanwhile, its current ROE is 54.08%. The company focused on small and mid-size companies. In this segment, the company has gained competitive advantages. Despite the fact that Medpace has received high backlog cancellations, the company is still a solid firm, and it grew by 9.81% between 2023 and 2024Q3 TTM. In the short term, the CRO market will face a difficult time, but the market outlook for the long term expects an improvement. Read the full article on Seeking AlphaSeeking Alpha • Oct 26
Medpace: Buy The Short-Term Pain For Long-Term Gains
Summary Medpace Holdings' stock fell after Q3 earnings due to revenue growth concerns and a low book-to-bill ratio, but the long-term prospects remain strong. Medpace offers full-service clinical trial management, catering mainly to small biopharma companies lacking trial expertise, making it a stand-out player in the CRO market. Despite short-term revenue growth issues, Medpace's financials are impressive, with high profitability, no debt, and strong returns on capital, justifying a Buy rating. The stock is reasonably priced, trading below historical averages, and is poised for long-term growth, especially if biopharma funding rebounds as expected. Read the full article on Seeking AlphaSeeking Alpha • Oct 16
Why Medpace Holdings Is A 'Better Mousetrap'
Summary Initiated a position in Medpace, increased investment after Q2 earnings miss; believe stock issues are temporary, presenting a buying opportunity. Medpace, a niche leader in CRO industry, operates under a full-service outsourcing model, serving small biotech companies with high-value, tailored solutions. Impressive financials: 20%+ revenue growth, 100%+ free cash flow conversion, 50%+ return on invested capital, large growth runway in a growing market. Stock price down 20% due to biotech R&D slowdown; long-term industry drivers intact, Medpace trading at an attractive valuation with superior growth prospects. Read the full article on Seeking Alpha
Ny berättelse • Aug 22
Temporary Setbacks Poised For A Swift Recovery And Strong Future Revenue Growth
Elevated project cancellations pose only a temporary risk, with potential for quick revenue and net new business awards recovery.Seeking Alpha • Aug 20
Medpace: Continued Business Growth With Asymmetrical Payoff Opportunity
Summary Medpace stock is up 69% since my original buy rating, backed by strong profitability and cash flow generation. Q2 earnings show continued growth and backlog strength, with potential for further value creation above opportunities of equal risk. Forward estimates on conservative assumptions imply the intrinsic worth of the business is above $400/share. Read the full article on Seeking AlphaFördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Medpace Holdings tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 2,678 | 460 | 188 | 0 |
| 31 Dec 25 | 2,530 | 451 | 198 | 0 |
| 30 Sep 25 | 2,358 | 433 | 198 | 0 |
| 30 Jun 25 | 2,232 | 418 | 199 | 0 |
| 31 Mar 25 | 2,157 | 416 | 194 | 0 |
| 31 Dec 24 | 2,109 | 404 | 180 | 0 |
| 30 Sep 24 | 2,071 | 366 | 177 | 0 |
| 30 Jun 24 | 2,030 | 340 | 169 | 0 |
| 31 Mar 24 | 1,963 | 312 | 167 | 0 |
| 31 Dec 23 | 1,886 | 283 | 161 | 0 |
| 30 Sep 23 | 1,782 | 273 | 152 | 0 |
| 30 Jun 23 | 1,673 | 268 | 146 | 0 |
| 31 Mar 23 | 1,563 | 257 | 140 | 0 |
| 31 Dec 22 | 1,460 | 245 | 131 | 0 |
| 30 Sep 22 | 1,374 | 227 | 126 | 0 |
| 30 Jun 22 | 1,286 | 209 | 118 | 0 |
| 31 Mar 22 | 1,213 | 199 | 112 | 0 |
| 31 Dec 21 | 1,142 | 181 | 108 | 0 |
| 30 Sep 21 | 1,094 | 182 | 103 | 0 |
| 30 Jun 21 | 1,028 | 175 | 98 | 0 |
| 31 Mar 21 | 955 | 159 | 93 | 0 |
| 31 Dec 20 | 926 | 145 | 92 | 0 |
| 30 Sep 20 | 896 | 124 | 91 | 0 |
| 30 Jun 20 | 882 | 107 | 97 | 0 |
| 31 Mar 20 | 891 | 110 | 99 | 0 |
| 31 Dec 19 | 861 | 100 | 95 | 0 |
| 30 Sep 19 | 823 | 93 | 95 | 0 |
| 30 Jun 19 | 786 | 88 | 84 | 0 |
| 31 Mar 19 | 742 | 78 | 81 | 0 |
| 31 Dec 18 | 705 | 73 | 76 | 0 |
| 30 Sep 18 | 612 | 61 | 72 | 0 |
| 30 Jun 18 | 531 | 52 | 70 | 0 |
| 31 Mar 18 | 456 | 45 | 64 | 0 |
| 31 Dec 17 | 386 | 39 | 63 | 0 |
| 30 Sep 17 | 382 | 28 | 63 | 0 |
| 30 Jun 17 | 379 | 23 | 63 | 0 |
| 31 Mar 17 | 377 | 18 | 63 | 0 |
| 31 Dec 16 | 371 | 13 | 62 | 0 |
| 30 Sep 16 | 361 | 5 | 65 | 0 |
| 30 Jun 16 | 348 | 0 | 60 | 0 |
| 31 Mar 16 | 332 | -5 | 57 | 0 |
| 31 Dec 15 | 320 | -9 | 54 | 0 |
Kvalitetsintäkter: MEDP har inkomster av hög kvalitet.
Växande vinstmarginal: MEDP s nuvarande netto vinstmarginaler (17.2%) är lägre än förra året (19.3%).
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: MEDP s intäkter har ökat markant med 21.6% per år under de senaste 5 åren.
Accelererande tillväxt: MEDP s intäktstillväxt under det senaste året ( 10.6% ) är under sitt 5-åriga genomsnitt ( 21.6% per år).
Resultat vs industri: MEDP vinsttillväxt under det senaste året ( 10.6% ) översteg Life Sciences branschen 3.8%.
Avkastning på eget kapital
Hög ROE: MEDP s avkastning på eget kapital ( 76.9% ) anses utestående.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/27 16:05 |
| Aktiekurs vid dagens slut | 2026/05/27 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Medpace Holdings, Inc. bevakas av 20 analytiker. 12 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Eric Coldwell | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |